New England Research & Management, Inc. Nektar Therapeutics Transaction History

New England Research & Management, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 04, 2019	SELL	$16.91 - $36.27 $187,785 - $402,778	-11,105 Closed	0 $0
Q2 2019 Jul 09, 2019	BUY	$31.0 - $36.3 $7,750 - $9,075	250 Added 2.3%	11,105 $395,000
Q1 2019 Apr 03, 2019	BUY	$31.58 - $46.35 $342,800 - $503,129	10,855 New	10,855 $365,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of New England Research & Management, Inc., based on Form 13F filings with the SEC.

Stay updated on New England Research & Management, Inc. with notifications on news.